The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) is a huge mover today! About 202,719 shares traded hands. Ocular Therapeutix Inc (NASDAQ:OCUL) has declined 32.99% since March 7, 2016 and is downtrending. It has underperformed by 40.58% the S&P500.
The move comes after 9 months positive chart setup for the $163.93M company. It was reported on Oct, 10 by Barchart.com. We have $18.63 PT which if reached, will make NASDAQ:OCUL worth $285.24 million more.
Analysts await Ocular Therapeutix Inc (NASDAQ:OCUL) to report earnings on November, 8. They expect $-0.51 earnings per share, down 8.51% or $0.04 from last year’s $-0.47 per share. After $-0.46 actual earnings per share reported by Ocular Therapeutix Inc for the previous quarter, Wall Street now forecasts 10.87% negative EPS growth.
Ocular Therapeutix Inc (NASDAQ:OCUL) Ratings Coverage
Out of 3 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ocular Therapeutix has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Nomura initiated it with “Buy” rating and $46 target price in Wednesday, August 5 report. The firm has “Overweight” rating given on Thursday, February 18 by Morgan Stanley. As per Thursday, August 13, the company rating was initiated by Morgan Stanley. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has “Overweight” rating given on Thursday, April 28 by Morgan Stanley. The rating was initiated by JMP Securities on Thursday, August 11 with “Outperform”. The stock of Ocular Therapeutix Inc (NASDAQ:OCUL) has “Overweight” rating given on Tuesday, June 7 by Morgan Stanley. The firm earned “Equal-Weight” rating on Friday, October 23 by Morgan Stanley.
According to Zacks Investment Research, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.”
More news for Ocular Therapeutix Inc (NASDAQ:OCUL) were recently published by: Businesswire.com, which released: “Ocular Therapeutixâ„¢ Announces FDA Acceptance of NDA Filing for DEXTENZAâ„¢ for …” on December 09, 2015. Businesswire.com‘s article titled: “Ocular Therapeutixâ„¢ Provides Update on NDA for DEXTENZAâ„¢ for the Treatment …” and published on August 03, 2016 is yet another important article.
OCUL Company Profile
Ocular Therapeutix, Inc., incorporated on September 12, 2006, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company’s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.